Immobilized Recombinant Human CDKN2A/p16INK4a Protein (rp188347) at 1.0 μg/mL can bind Recombinant CDKN2A/p16INK4a Antibody (Ab095843) with the EC50 of 7.2 ng/mL.
CDKN2A germline mutations increase the risk of melanoma development. CDKN2A/CDK4 were the first high-penetrance melanoma genes identified. CDKN2A suppresses the initiation of melanoma invasion through inhibition of BRN2. It's a potential prognostic role of CDKN2A/B deletions in early disease stratification in pediatric B-ALL. CDKN2A coding region germline variants are associated with pancreatic adenocarcinoma (PC) susceptibility.
Post-translational: Phosphorylation seems to increase interaction with CDK4.
生物活性
Immobilized Recombinant Human CDKN2A/p16INK4a Protein (rp188347) at 1.0 μg/mL can bind Recombinant CDKN2A/p16INK4a Antibody (Ab095843) with the EC50 of 7.2 ng/mL.
14.8 kDa, under reducing conditions; 14.8 & 33.4 kDa, under non-reducing conditions.
分子类型
蛋白质
产品线
生物产品
储存与运输
物理形态
液体
储存缓冲液
PBS, 5% Glycerol, pH 7.4
浓度
见COA
复溶
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute at 1.0 mg/mL in sterile distilled water. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
储存条件
-20°C储存,避免反复冻融
运输条件
超低温运输
稳定性与储存
-20℃(12个月);收货后建议分装,避免反复冻融。
图片
Recombinant Human CDKN2A/p16INK4a Protein (rp188347) - ELISA Immobilized Recombinant Human CDKN2A/p16INK4a Protein (rp188347) at 1.0 μg/mL can bind Recombinant CDKN2A/p16INK4a Antibody (Ab095843) with the EC50 of 7.2 ng/mL.
Recombinant Human CDKN2A/p16INK4a Protein (rp188347) - SDS-PAGE 3 μg/lane of Recombinant Human CDKN2A/p16INK4a Protein was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing a band at 14.8 kDa under reducing conditions and 14.8 & 33.4 kDa non-reducing conditions. Disulfide bonds cause protein has a dimer form under non-reducing conditions (Uniprot: P42771).